- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04569851
Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019)
Clinical Characteristics and Prognostic Factors of Patients With COVID-19 Using Big Data and Artificial Intelligence Techniques (BigCoviData)
Study Overview
Status
Conditions
Detailed Description
Data captured in the EHRs will be collected from all available departments, including inpatient hospital, outpatient hospital, emergency room, etc. for virtually all types of provided services in each participating site. The study period will be from January 1, 2020 to the most recent data available.
- Primary objective To determine factors that predict disease prognosis and outcomes in COVID-19 patients, specifically: Hospitalization/Off-site monitoring, transfer to ICU and/or need for medical mechanical ventilation (both invasive and non- invasive), length of ICU stay, and outcome (cure/ hospital discharge, in-hospital death)
Secondary objectives
- To describe the demographic and clinical characteristics of COVID-19 patients
- To describe the patient management (treatment and procedures) in the target population
- To describe the outcomes of COVID-19 (discharge, hospitalization, transfer to ICU/ mechanical medical ventilation, in-hospital death) in relation to patients' clinical and demographic characteristics, and treatment received
- To determine whether the factors that predict COVID-19 prognosis and outcome also apply to other types of pneumonia.
- Exploratory objectives One of the goals of this study is to configure the Big Data system to unravel any hidden variable/s (and their associations) that may offer novel clinical insights into COVID-19 management.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Guadalajara, Spain
- Hospital Universitario de Guadalajara
-
Madrid, Spain
- Hospital Universitario La Princesa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
The study population will consist of all patients with suspected COVID-19 infection, as captured in the patients' EHRs of the participating sites.
Among the suspected COVID-19 cases, we will determine the following:
- Confirmed positive cases (i.e., all patients who tested positive for COVID-19 ).
- Confirmed negative cases (i.e., all patients who tested negative for COVID-19)
- Possible cases (i.e., all patients with suspected COVID-19 but no/pending test results) To determine the characteristics of the patients according to their clinical outcome, we will study both the confirmed positive cases and all possible classes (with no/pending laboratory results) subpopulations
Description
Inclusion Criteria:
- All patients with suspected COVID-19 infection, as captured in the patients' EHRs of the participating sites.
Exclusion Criteria:
- Not suspected COVID-10 infection
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Factors that predict disease prognosis and outcomes in COVID-19 patients - Hospitalization
Time Frame: From 1st Jan 2020
|
All variables and outcomes will be extracted from the free-text narratives available in patients' EHRs Hospitalization
|
From 1st Jan 2020
|
Factors that predict disease prognosis and outcomes in COVID-19 patients - ICU
Time Frame: From 1st Jan 2020
|
Transfer to ICU and/or need for medical ventilation
|
From 1st Jan 2020
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The demographic and clinical characteristics of COVID-19 patients
Time Frame: From 1st Jan 2020
|
Gender (% of male patients; % of female patients)
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients-Age at diagnosis
Time Frame: From 1st Jan 2020
|
Age (in years) at diagnosis
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients -Percentage of patients in each age range
Time Frame: From 1st Jan 2020
|
Percentage of patients in each age range (<2; 2-4; 5-14; 15-29; 30-39; 40-49; 50-59; 60-69; 70-79; >= 80).
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients with available PCR (Polymerase Chain Reaction) results
Time Frame: From 1st Jan 2020
|
Percentage of patients with available PCR results (Positive; Negative; Unknown) Percentage of patients with available IgG (immunoglobulin G)/IgM (immunoglobulin M) results (Positive; Negative; Unknown) Percentage of patients using Alcohol/Tobacco/Other substances (Yes/No/Former user/Unknown
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patientsTime since first symptom until diagnosis
Time Frame: From 1st Jan 2020
|
Time (in days) since first symptom until diagnosis
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Physical examination
Time Frame: From 1st Jan 2020
|
Physical examination
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Physical examination of patients who are pregnant
Time Frame: From 1st Jan 2020
|
Physical examination
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Physical examination Temperature
Time Frame: From 1st Jan 2020
|
Physical examination
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Physical examination Heart rate (bmp)
Time Frame: From 1st Jan 2020
|
Physical examination
|
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Hemoglobin
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Hematology: Hemoglobin (g/dl) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Hemoglobin II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Hematology: Hemoglobin n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Red Blood Cells
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Hematology: Red Blood Cells (106/µl) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Red Blood Cells II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Hematology: Red Blood Cells n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology: Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Hematology: Platelet count (103/mm3) Leukocyte count (103/mm3) Neutrophils (103/mm3) Lymphocytes (103/mm3) Monocytes (103/mm3) Eosinophils (103/mm3) Basophils (103/mm3) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology: Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Hematology: Platelet count n(%) Leukocyte count n(%) Neutrophils n(%) Lymphocytes n(%) Monocytes n(%) Eosinophils n(%) Basophils n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology- INR (International Normalized Ratio)
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Hematology: INR n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology- INR II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Hematology: INR |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Glucose, Cholesterol, Triglycerides
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Biochemistry: Glucose (mg/dl) Total cholesterol (mg/dl) Triglycerides (mg/dl) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Glucose, Cholesterol, Triglycerides II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Biochemistry: Glucose n(%) Total cholesterol n(%) Triglycerides n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Bilirubin
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Biochemistry: Total bilirubin (g/dL) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Bilirubin II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Biochemistry: Total bilirubin n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Creatinine, Glucose
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other values: Creatinine in urine (mg/dl) Glucose in urine (mg/dl) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Creatinine, Glucose II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other values: Creatinine in urine n(%) Glucose in urine n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Procalcitonin
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other values: Procalcitonin level will be reported" (PCT) ng/mL |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH (Potential Hydrogen), O2 Saturation, FIO2 (Fractional Inspired Oxigen), PAFI [Blood pressure of oxygen / inspired fraction of oxygen (PaO2/FiO2)]
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other tests: pH pH n(%) O2 saturation (%) O2 saturation n(%) FIO2 (%) FIO2 n(%) PAFI (%) PAFI n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other tests: pH |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other tests: PH n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: O2 saturation, FIO2, PAFI
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other tests: O2 saturation (%) FIO2 (%) PAFI (%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: O2 saturation, FIO2, PAFI II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other tests: O2 saturation n(%) FIO2 n(%) PAFI n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: pCO2 (partial pressure of carbon dioxide), pO2 (partial pressure of oxygen)
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other tests: pCO2 (mmHg) pO2 (mmHg) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: pCO2, pO2 II
Time Frame: From 1st Jan 2020
|
Physical examination. Laboratory values at diagnosis Other tests: pCO2 n(%) pO2 n(%) |
From 1st Jan 2020
|
The demographic and clinical characteristics of COVID-19 patients- Comorbidities, Medication, Symptoms
Time Frame: From 1st Jan 2020
|
|
From 1st Jan 2020
|
The patient management (treatment and procedures) in the target population
Time Frame: From 1st Jan 2020
|
Percentage of patients assigned to the following procedures after diagnosis: Chest x-ray, Ultrasonography of thorax,Ultrasonography of lung, High resolution computed tomography, Computer tomography of chest, Echocardiogram, EKG Percentage of patients assigned to the following treatments after diagnosis: Oxygen therapy (Oxygen administration by nasal cannula, Oxygen administration by Venturi mask, High concentration oxygen therapy), Prone position, Noninvasive ventilation, Invasive mechanical ventilation,Tracheotomy, Extubation of trachea. Percentage of patients (and mean duration of treatment in days) prescribed with the following pharmacological agents after diagnosis: Lopinavir + Ritonavir, Darunavir + Ritonavir, Darunavir + Cobicistat, IFN (Interferon)- β1b, Chloroquine, Hydroxychloroquine, Antibiotics, Acetylcysteine,Corticosteroids,Selective immunosuppressants, Cyclosporine, Remdesivir, Antithrombotic agents (anticoagulants), Inhibitors of platelet aggregation. |
From 1st Jan 2020
|
The outcomes of COVID-19 (discharge, hospitalization, transfer to ICU/ mechanical medical ventilation, in-hospital death) in correlation to patients' clinical and demographic characteristics, and treatment received
Time Frame: From 1st Jan 2020
|
The outcomes of COVID-19 (discharge, hospitalization, transfer to ICU/ mechanical medical ventilation, in-hospital death) in correlation to patients' clinical and demographic characteristics, and treatment received
|
From 1st Jan 2020
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: José Luis Izquierdo, MD, PhD, Hospital Universitario de Guadalajara
- Study Chair: Joan B Soriano, MD, PhD, Hospital Universitario La Princesa
- Study Chair: Julio Ancochea, MD, PhD, Hospital Universitario La Princesa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BigCoviData
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Infection
-
Aga Khan UniversityCompletedCOVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Lower Respiratory InfectionPakistan
-
Catalysis SLCompletedRespiratory Tract Infections | Covid19 | SARS-CoV2 Infection | COVID-19 Pneumonia | COVID-19 Respiratory Infection | Viral Infection | Infection, CoronavirusKazakhstan
-
KARE BiosciencesBiomedical Advanced Research and Development Authority; BioLink Life Sciences... and other collaboratorsRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory InfectionIndia
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
bioLytical LaboratoriesCompletedCOVID-19 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19United States
-
Tiziana Life Sciences LTDWithdrawnCovid19 | COVID-19 Respiratory Infection | COVID-19 Lower Respiratory Infection
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...Active, not recruitingAsymptomatic COVID-19 Infection Laboratory-Confirmed | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
Patrick RobinsonRecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute BronchitisUnited States
-
Mahidol UniversityClinixir Co., Ltd.; Program Management Unit-C (PMU-C), governed by Ministry...CompletedCOVID-19 Infection | COVID-19 VACCINEThailand
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina